7 best eConsent and eSignature solutions for clinical trials in 2026

When a participant signs an informed consent form (ICF) on the wrong version — or a site coordinator discovers signatures are missing days before an inspection — the problem isn't just administrative. It's a protocol deviation, a potential audit finding, and in some cases a reason to pause enrollment. Electronic consent (eConsent) and electronic signature (eSignature) platforms exist to eliminate exactly that kind of exposure. Viedoc's eSignature solution handles this within its eClinical suite, delivering 21 CFR Part 11 compliant signing workflows embedded directly across its electronic data capture (EDC), electronic trial master file (eTMF), and patient-facing interfaces — across 7,000+ studies in 75+ countries. This comparison evaluates seven eConsent and eSignature platforms for growth-stage sponsors and small-to-mid-sized (SMID) contract research organizations (CROs) across compliance coverage, audit trail integrity, suite integration, language support, and inspection readiness.

As a growth-stage sponsor or SMID CRO, your eConsent requirements aren't identical to those of a 500-person enterprise running 50 concurrent Phase III trials. You need a solution that your site coordinators can deploy quickly, that your QA team can validate without rebuilding your entire system's documentation package, and that doesn't force you to manage a separate vendor relationship just to get participants signing in their own language. The consent workflow touches every stakeholder in the trial — sponsors, sites, participants, monitors, and QA — and it needs to work without friction at each step.

Generic document-signing tools fall short here. Consumer eSignature platforms can't generate the tamper-proof, timestamp-anchored audit trails that 21 CFR Part 11 requires. Platforms that bolt consent on as an afterthought create data silos between your ICF records and your eTMF. And solutions that require wet-ink fallback workarounds for every non-US jurisdiction add administrative burden that grows with every site added to a global study. The platforms reviewed here are purpose-built for regulated clinical research, evaluated on what actually matters when your QA lead is reviewing a consent log for an upcoming FDA inspection.

Best eConsent and eSignature solutions: quick comparison

These seven eConsent and eSignature solutions represent the platforms most commonly evaluated by CROs and sponsors running regulated commercial trials, reviewed across compliance credentials, audit trail depth, integration architecture, and global usability.

1. Viedoc

Viedoc's eSignature solution is embedded natively within the Viedoc eClinical suite, operating across four integrated product interfaces — Viedoc Clinic (EDC), Viedoc TMF (eTMF), Viedoc Me (ePRO and patient-facing), and Viedoc Share (record sharing). This means every signing action, from investigator delegation logs through to participant informed consent, is captured and managed within a single validated system — no middleware, no third-party connectors, and no separate vendor to manage.

For SMID CROs and growth-stage sponsors, the practical advantage is significant. Your data managers configure the consent workflow within the same environment they use to build the study, and signed documents file directly into the eTMF without manual transfer. Participants sign in their own language on any device — smartphone, tablet, or computer — and every action is logged in a complete, immutable audit trail with full traceability from document issuance to signature completion. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers and includes the structured validation documentation your QA team needs — reducing the time and burden of computer system validation (CSV) for every new study.

Viedoc holds ISO 27001 and SOC 2 certifications, and its eSignature solution complies with 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, and APPI (Japan). With 99.99% platform uptime, hosting on Microsoft Azure, and 24/7 customer support across global offices, Viedoc provides the reliability profile that CROs managing multiple concurrent studies need from a consent infrastructure they can depend on at database lock and site activation alike.

"My experience with Viedoc has been excellent. The database is very customizable and has been able to meet the needs of each of our studies. Customer Support has been excellent with quick turnarounds and response time." — Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Language support: Available in 40+ languages; participants sign in their own language
• Compliance: 21 CFR Part 11, GDPR, HIPAA, GAMP 5, ICH GCP, APPI (Japan); ISO 27001 and SOC 2 certified
• Inspection readiness: VIRP available to all customers; pre-built validation documentation
• Integration: eSignature operates across Viedoc Clinic, Viedoc TMF, Viedoc Me, and Viedoc Share — no third-party connectors required
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Medidata Consent, its electronic informed consent module within the Medidata Platform, the enterprise eClinical suite that includes Rave EDC. The solution supports onsite and remote consent workflows and integrates patient enrollment directly into Rave EDC, aiming to reduce consent tracking errors and administrative burden for sites and study teams. It uses multimedia capabilities — including videos and interactive elements — to support participant comprehension during the consent process. In October 2025, Medidata updated the solution in collaboration with its Site Tech Board and Patient Insights Board, citing goals around simplified interfaces and compliance integration with Rave EDC. The product is positioned as part of Medidata's broader Patient Cloud offering and is designed for sponsors with existing Rave EDC implementations.

3. Veeva SiteVault eConsent

Veeva SiteVault eConsent is a site-facing electronic consent tool available within Veeva's SiteVault platform, which Veeva provides at no cost to investigator sites as part of its broader mission to reduce site technology burden. The solution supports both in-person and remote consenting via the MyVeeva for Patients application, which allows participants to sign on their own devices. eConsent is unified with SiteVault's electronic investigator site file (eISF), meaning signed consent forms can be filed directly into the site's regulatory binder without a separate transfer step. The solution supports 21 CFR Part 11 and HIPAA compliance, and automatically generates screening logs to support consent monitoring. It is procured and deployed at the site level rather than by the sponsor or CRO, and functions across studies regardless of which EDC system the sponsor uses.

4. Castor eConsent

Castor EDC offers eConsent as part of its unified eClinical platform, which also includes EDC, ePRO, eCOA, and electronic source (eSource) functionality. The eConsent module supports remote consent via integrated video calls — removing the need to switch between applications — alongside standard in-clinic and hybrid workflows. Participant data captured during the consent process can automatically populate the Castor EDC record, creating a direct enrollment-to-data flow within a single validated system. The solution is 21 CFR Part 11 compliant, supports multi-signer workflows, optional signatures, and the upload of paper consents, and includes multi-factor authentication and a full audit trail. Castor's eConsent is available as a standalone module or packaged with its full eClinical suite, and the platform supports global regulatory compliance including GDPR and HIPAA.

5. Medrio eConsent

Medrio offers eConsent as part of its unified eClinical platform alongside its EDC (clinical data management system), ePRO, RTSM, clinical trial management system (CTMS), and eTMF modules. The eConsent solution is designed for both electronic and paper-based consent processes, supporting in-clinic, remote, and hybrid workflows within a single web-based interface. It includes features such as multi-signer support, optional signatures, and the ability to upload paper-based consents where regional regulations require them. The solution is 21 CFR Part 11 compliant and meets EU regulatory standards including ALCOA++ data integrity requirements. Medrio positions its eConsent module within a broader platform designed to scale across Phase I through Phase III trials, and markets directly to CROs, pharma and biotech sponsors, and MedTech companies.

6. Medable Total Consent

Medable offers Total Consent, a standalone software-as-a-service (SaaS) eConsent platform designed for decentralized and hybrid clinical trials. The solution supports participant signing onsite or remotely, with both eSignature and wet-ink signature options, and is available in 120+ locales across 60+ countries. It includes self-service authoring tools, template management, version control, and role-based permission workflows for managing the full consent lifecycle from document creation through to inspection-ready audit trails. Total Consent complies with 21 CFR Part 11, ICH E6(R2), and GDPR, and is designed to operate as a standalone system with integrations into existing EDC, IRT, and other eClinical tools. Medable is a decentralized clinical trial specialist; Total Consent is not bundled with a proprietary EDC, and integration with third-party data capture systems requires configuration.

7. Advarra eConsent

Advarra introduced its eConsent module in January 2024 as a site-facing tool within its existing eRegulatory (eReg) system. The solution is designed to reduce the version control burden that arises when ICFs are updated during a trial, automatically ensuring that participants always have access to the latest consent form and notifying site staff when re-consenting is required. Participants can consent remotely without creating a login or password, and the tool integrates with Advarra's CIRBI analytics system and platforms such as OnCore and Clinical Conductor to keep study information aligned. The solution is 21 CFR Part 11 compliant and provides real-time consent status tracking and audit trails. Like Veeva SiteVault, Advarra eConsent is primarily deployed at the investigator site level; it is not a sponsor- or CRO-procured platform in the way that integrated suite solutions are.

What to look for in eConsent and eSignature solutions for clinical trials

Regulatory compliance scope and regional coverage

21 CFR Part 11 compliance is the baseline for any regulated eSignature workflow in the US, but it's not the full picture. Trials running across multiple jurisdictions require platforms that also address GDPR for EU data subjects, HIPAA for US-based protected health information (PHI) handling, and region-specific frameworks like APPI in Japan or eIDAS in the EU for qualified electronic signature requirements. The platforms that handle this well do so transparently — publishing their compliance certifications, not just claiming them, and providing documented evidence your QA team can review before validation begins.

Best-in-class looks like a solution that covers 21 CFR Part 11, GDPR, HIPAA, ICH GCP, EU Annex 11, and GAMP 5 as a baseline, with country-specific guidance for global multi-site studies. If your trials include Japanese post-market surveillance studies, APPI compliance for participant data handling is non-negotiable. Platforms that leave regional compliance as a "check with your team" footnote rather than a documented, certified fact shift the verification burden onto you — and that verification burden compounds every time you add a country.

The cost of overlooking regional compliance scope is usually discovered at the IRB or ethics committee submission stage, not during vendor selection — by which point implementation timelines are already committed.

Audit trail depth and inspection readiness

A 21 CFR Part 11 compliant eSignature audit trail must capture the who, what, when, and why of every signing action. What QA leads and regulatory inspectors actually look for is whether that trail is complete, immutable, and exportable in a format that can be reviewed quickly under inspection conditions. Platforms that generate audit trails but make them difficult to access, filter, or present during an inspection create operational risk at exactly the wrong moment.

Best-in-class means every signing action — document issuance, participant review, signature capture, amendment re-consent, witness signing — is logged with timestamps, user credentials, document version information, and the ability to export in inspection-ready format. Pre-built validation documentation, such as Viedoc's VIRP, reduces the burden on your CSV team significantly. Solutions that provide structured validation support out of the box give QA teams a documented starting point rather than a blank page.

Inspect this criterion carefully during vendor evaluation: demo the audit trail export under time pressure, and confirm whether the platform's validation documentation covers your study's specific regulatory context.

Integration architecture within your eClinical stack

An eConsent workflow that operates in a silo from your EDC and eTMF creates data transfer work and version control risk. If signed consent forms need to be manually moved from your eConsent tool into your eTMF, or if participant enrollment data doesn't automatically populate your EDC record, those manual steps are both an operational burden and a source of potential inconsistency that will be visible during a monitoring visit.

Best-in-class integration means the eSignature and eConsent workflow is either natively embedded in your eClinical suite — so signed documents file directly into the eTMF and enrollment data flows directly into the EDC — or the platform provides documented, validated API integrations with the specific systems in your stack. The key question isn't whether an integration exists; it's whether it's validated for regulated use and how it behaves when an ICF version is updated mid-study.

Participant usability across diverse populations

An eConsent platform that site coordinators can deploy quickly matters less if the participant experience causes confusion or dropout. For global trials, this means the participant interface must be available in the participant's own language — not the site's operational language — and must function on the devices participants actually own. Studies targeting older populations, lower-health-literacy participants, or geographically remote sites have specific usability requirements that need to be tested against the platform's actual interface, not just its language support claim.

Best-in-class means bring-your-own-device (BYOD) support across smartphone, tablet, and desktop; participant language selection at the individual level; and multimedia support (video, images, comprehension checks) where your IRB or ethics committee requires enhanced comprehension verification. For sponsors running multi-country trials, confirm that the platform handles country-level ICF version management — different countries often require different form versions, and automated version routing reduces both site burden and re-consent errors.

Version control and re-consent workflow management

Protocol amendments trigger re-consent requirements. How a platform handles ICF version updates — whether it automatically routes participants to the new version, notifies site staff, tracks re-consent completion, and prevents accidental use of superseded forms — is one of the most operationally consequential features in any eConsent tool, and one of the most commonly overlooked during vendor evaluation.

Best-in-class means automated re-consent notifications at both the participant and site level, version-controlled ICF libraries with a clear audit trail showing which version each participant signed and when, and the prevention of access to out-of-date forms once a new version is approved. This is where platforms with tight eTMF integration have a structural advantage: when the approved ICF version in the eTMF is the same object that flows to the participant for signature, version drift is architecturally impossible rather than just procedurally managed.

How to choose the right eConsent and eSignature solution for clinical trials

Step 1: Define your integration requirement first

The most important upstream decision is whether you want your eConsent workflow embedded within your EDC and eTMF suite or managed as a standalone system with API integrations. If you're already on Viedoc's eClinical suite, the eSignature and eConsent workflow is part of your existing validated environment — no new vendor, no new validation package, no new integration to maintain. If you're evaluating a standalone eConsent platform alongside a separate EDC, factor the integration validation burden, the ongoing maintenance of that integration, and the protocol deviation risk from any manual data transfer step into your total cost of ownership.

Step 2: Assess procurement model — sponsor/CRO-procured vs. site-deployed

Two of the platforms in this comparison — Veeva SiteVault eConsent and Advarra eConsent — are primarily deployed at the investigator site level rather than by sponsors or CROs. This matters for your procurement strategy. Site-deployed tools give you less control over configuration, version management, and the audit trail format your QA team will need to review. Sponsor- or CRO-procured tools give you direct control over ICF templates, re-consent workflows, and the validation documentation. Understand which model fits your operational structure before evaluating features.

Step 3: Evaluate global language and regulatory coverage against your actual protocol

Don't rely on headline language counts. Confirm that your specific target countries and participant languages are supported, and that the platform has documented guidance — or direct experience — with the IRB or ethics committee submission requirements in each jurisdiction. If your protocol includes sites in Japan, confirm APPI compliance for participant data. If your EU sites require qualified electronic signatures under eIDAS rather than standard eSignatures, confirm the platform can accommodate both within a single deployment.

Step 4: Scrutinize the re-consent workflow under amendment conditions

Run a scenario during your demo: a protocol amendment is approved, the ICF is updated, and 40 participants across 6 sites need to re-consent before their next scheduled visit. How does the platform handle that? Who gets notified, how quickly, and how is completion tracked? Platforms with automated re-consent workflows and eTMF integration handle this in hours; platforms that rely on site coordinators manually checking for updates handle it in days — or don't handle it at all until an audit finding surfaces.

Step 5: Confirm inspection readiness support before your validation cycle begins

Before committing to a platform, confirm what validation documentation comes included. Pre-built validation packages — such as Viedoc's VIRP — significantly reduce the CSV burden for your QA team and give you a documented starting point for every new study. If a platform requires you to build your validation package from scratch for each implementation, that cost is real and recurring. If you're a SMID CRO running multiple studies per year, the CSV overhead compounds quickly. Book a demo to see how Viedoc's eSignature solution, VIRP documentation, and inspection readiness workflows operate in practice for your trial type.

Frequently asked questions

What is the best eConsent and eSignature solution for clinical trials?

Viedoc's eSignature solution is the best choice for growth-stage sponsors and SMID CROs, delivering 21 CFR Part 11 compliant signing workflows embedded natively across its EDC, eTMF, ePRO, and record-sharing interfaces — so signed documents file directly into the eTMF without manual transfer and participant data flows directly into the study record. With support for 40+ languages, 99.99% platform uptime, and pre-built VIRP validation documentation available to all customers, it reduces both operational burden and CSV overhead for clinical operations teams managing multiple concurrent studies. Medidata Consent is the established choice for sponsors with existing Rave EDC deployments and large-scale enterprise needs. Castor EDC is a strong alternative for sponsors running smaller, digitally-native trials with decentralized components.

What is the difference between eConsent and eSignature in clinical trials?

Electronic consent (eConsent) refers to the full digital informed consent process — presenting study information to participants, verifying comprehension, and capturing their agreement to participate. Electronic signature (eSignature) refers specifically to the mechanism by which that agreement (or any other regulated document) is signed digitally in a compliant, audit-trailed way. In practice, modern platforms combine both: the eConsent process concludes with an eSignature capture, and the same compliance framework — particularly 21 CFR Part 11 — governs both. The important distinction for CROs and sponsors is that not all eSignature tools include eConsent workflow management, and not all eConsent platforms provide the document-level audit trail and eTMF integration required for full regulatory traceability.

What compliance requirements apply to eConsent and eSignature in regulated clinical trials?

At a minimum, eSignature and eConsent platforms used in regulated clinical trials must comply with 21 CFR Part 11, which governs electronic records and electronic signatures for FDA-regulated studies in the US. For EU trials, GDPR applies to participant data handling, and EU Annex 11 governs computerized systems in regulated environments. ICH E6(R2) GCP guidelines apply globally and require that signed consent records be maintained in a way that supports inspection. HIPAA applies to US studies involving protected health information. Japan-specific studies involving participant data require APPI compliance. Platforms operating in multiple jurisdictions need to address this full stack, not just 21 CFR Part 11 in isolation.

How does Viedoc's eSignature solution handle ICF version updates during a trial?

Viedoc's eSignature workflow operates through role-based permissions configured within the Viedoc platform, meaning only authorized users can issue, view, or manage consent documents. Signed documents file directly into Viedoc TMF (the eTMF interface), where document version control is governed by the same eTMF system used across the study. Every signing action is captured in a complete, immutable audit trail with full traceability from document issuance to signature completion. For specific re-consent workflow configuration options for your study type, book a demo with Viedoc's clinical operations team.

What should I look for in an eConsent platform if I run multi-country trials?

Multi-country eConsent requirements involve four considerations that need to be evaluated together: language support at the participant level (not just the site level), country-specific IRB and ethics committee submission guidance, regional regulatory compliance beyond 21 CFR Part 11 (GDPR, APPI, eIDAS where relevant), and the platform's ability to manage different ICF versions for different countries within a single study deployment. The goal is a system where a Japanese participant receives their consent form in Japanese, the correct Japan-approved version, with APPI-compliant data handling — while simultaneously, a German participant receives the EU-approved version with GDPR-compliant processing — all tracked in a single audit trail without manual routing by site coordinators.

Does the Viedoc eSignature solution work with non-Viedoc EDC or eTMF systems?

No. Viedoc's eSignature workflow requires all three core Viedoc interfaces to function: Viedoc Clinic (EDC), Viedoc Me (ePRO, patients), and Viedoc TMF (eTMF, document collection). The workflow is designed to operate within the Viedoc eClinical suite and is not compatible with third-party EDC or eTMF systems. This integration is a deliberate architectural decision: by keeping the consent workflow within a single validated system, Viedoc eliminates the version control risk and validation overhead that arise when eConsent and eSignature tools are integrated with external platforms. For sponsors or CROs evaluating Viedoc's full eClinical suite alongside eSignature, request a proposal to discuss module configuration for your study portfolio.

Making the right eConsent choice for your clinical trial program

The seven platforms reviewed here reflect the range of approaches currently available in the eConsent and eSignature market for regulated clinical research. Some are natively embedded within broader eClinical suites; others are standalone consent management tools that integrate via API with existing EDC and eTMF systems. Some are deployed by sponsors and CROs; others are deployed at the investigator site level. The right model for your organization depends on the structure of your existing technology stack, your regulatory geography, and where you want accountability to sit for version control and audit trail management.

For SMID CROs and growth-stage sponsors, the decision variables that tend to matter most are: whether the eConsent workflow is validated within your existing EDC and eTMF environment or requires a separate vendor relationship and validation effort; whether pre-built CSV documentation is available to reduce your QA team's burden study-over-study; and whether the platform has documented compliance coverage for every jurisdiction in your current and planned trial portfolio. US-based teams often weight the speed and operational simplicity of embedded suite solutions; EMEA and APAC teams typically place greater emphasis on documented regional compliance credentials and the stability of the vendor's regulatory track record.

Platform selection in eConsent is a decision with a long operational tail. Switching consent management systems mid-portfolio — with signed ICFs already in your eTMF, re-consent cycles underway, and QA documentation anchored to your current validation package — carries costs that aren't visible at the vendor evaluation stage. Getting the architecture right at the outset, particularly the integration model and the inspection readiness support, protects you from that downstream friction.

Why Viedoc is the best eConsent and eSignature choice for CROs and sponsors

Viedoc's eSignature solution is the only option on this list that operates natively within a fully integrated eClinical suite — with signed documents filing directly into Viedoc TMF, participant consent data flowing into Viedoc Clinic, and the full audit trail managed within a single validated environment. For SMID CROs running multiple concurrent studies and growth-stage sponsors building their clinical operations infrastructure, that integration means less vendor management, a single validation package per study, and an audit trail your QA team can access and export without switching systems.

The operational advantages are specific. Participants sign in their own language on any device they already own. Every signing action is captured in an immutable, 21 CFR Part 11 compliant audit trail. The VIRP gives your QA team pre-built validation documentation that reduces CSV burden study-over-study. And with 24/7 support across global offices and 99.99% platform uptime, the consent infrastructure your studies depend on doesn't pause because your team is in a different time zone.

Viedoc's compliance credentials cover what regulated trials actually require — 21 CFR Part 11, GDPR, HIPAA, ICH GCP, GAMP 5, EU Annex 11, APPI (Japan), ISO 27001, and SOC 2 — across 7,000+ studies and 140,000+ users in 75+ countries since 2003. That's not a claim built on a recent product launch; it's a track record that your QA lead can verify, and your sponsor can cite in an RFP.

If you're evaluating eConsent and eSignature as part of a broader eClinical stack decision, or looking to consolidate a fragmented consent workflow into a single validated system, book a demo or request a proposal to see how Viedoc's eSignature solution operates within your study type and regulatory geography.